Recent Updates
Recently added Catalysts

Prozac Pulvules

Phase 1

Healthy | Small molecule | Other |Viatris Inc.|Last Updated: Apr 24, 2024

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedACTIVE_CONTROLLEDBiomarker
Total Trials1
Total Enrollment32
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00649636Fasting Study of Fluoxetine Capsules 40 mg and Prozac Pulvules 40 mgPHASE1 COMPLETED 32Feb 1, 2006Apr 1, 2006Apr 24, 20241 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Bioequivalence
within 30 days
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelCROSSOVER
PurposeOTHER
Treatment Arms
ArmTypeDescription
1EXPERIMENTALFluoxetine Capsules 40 mg
2ACTIVE_COMPARATORProzac Pulvules 40 mg
Interventions
NameTypeDescription
Fluoxetine Capsules 40 mgDRUG40mg, single dose fasting
Prozac Pulvules 40 mgDRUG40mg, single dose fasting
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: 1. Age: 18 years and older. 2. Sex: Male and/or non-pregnant, non-lactating female. a. Women of childbearing potential must have negative serum beta human chorionic gonadotropin (b-HCG) pregnancy tests performed within 21 days prior to the start of the study and on the evening p...

Countries:United States
Unlock Eligibility Criteria